IRIS
CANTONETTI, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 35.309
AS - Asia 3.844
EU - Europa 3.675
SA - Sud America 547
Continente sconosciuto - Info sul continente non disponibili 322
AF - Africa 69
OC - Oceania 12
Totale 43.778
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 35.048
SG - Singapore 1.707
CN - Cina 903
DE - Germania 853
IT - Italia 548
RU - Federazione Russa 466
BR - Brasile 449
UA - Ucraina 431
HK - Hong Kong 391
IE - Irlanda 338
VN - Vietnam 308
GB - Regno Unito 284
FR - Francia 243
CA - Canada 180
FI - Finlandia 155
KR - Corea 119
SE - Svezia 119
BD - Bangladesh 108
JP - Giappone 85
PL - Polonia 65
IN - India 44
MX - Messico 44
AR - Argentina 33
AT - Austria 30
NL - Olanda 30
BE - Belgio 29
ID - Indonesia 26
EC - Ecuador 22
ZA - Sudafrica 21
IQ - Iraq 20
ES - Italia 19
KE - Kenya 18
TR - Turchia 16
CZ - Repubblica Ceca 15
PH - Filippine 15
JM - Giamaica 14
UZ - Uzbekistan 14
AU - Australia 11
CH - Svizzera 11
EU - Europa 10
IL - Israele 10
TH - Thailandia 10
VE - Venezuela 10
CO - Colombia 9
RO - Romania 9
SA - Arabia Saudita 9
PK - Pakistan 8
CL - Cile 7
UY - Uruguay 6
CR - Costa Rica 5
EG - Egitto 5
GT - Guatemala 5
MA - Marocco 5
MY - Malesia 5
PE - Perù 5
PY - Paraguay 5
TN - Tunisia 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
KG - Kirghizistan 4
LB - Libano 4
NG - Nigeria 4
NO - Norvegia 4
TT - Trinidad e Tobago 4
BG - Bulgaria 3
DZ - Algeria 3
GE - Georgia 3
HR - Croazia 3
JO - Giordania 3
KZ - Kazakistan 3
LT - Lituania 3
NP - Nepal 3
OM - Oman 3
AM - Armenia 2
BB - Barbados 2
BW - Botswana 2
EE - Estonia 2
GR - Grecia 2
HU - Ungheria 2
IR - Iran 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
MK - Macedonia 2
NI - Nicaragua 2
PT - Portogallo 2
SN - Senegal 2
SV - El Salvador 2
TG - Togo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CM - Camerun 1
DK - Danimarca 1
HT - Haiti 1
KH - Cambogia 1
MN - Mongolia 1
Totale 43.461
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.266
Wilmington 8.717
Houston 7.681
Ashburn 962
Singapore 885
Ann Arbor 810
Fairfield 770
Chandler 585
San Jose 526
Jacksonville 394
Hong Kong 388
Beijing 363
Seattle 343
New York 342
Dublin 324
Cambridge 279
Medford 238
Dearborn 198
Council Bluffs 182
Munich 172
Rome 172
Santa Clara 167
Los Angeles 134
Lawrence 114
Mcallen 111
Montréal 110
The Dalles 103
Ho Chi Minh City 99
Buffalo 82
Moscow 80
Lauterbourg 77
Zhengzhou 73
Tokyo 71
Hanoi 69
Mülheim 68
Dallas 65
Helsinki 60
São Paulo 59
Milan 55
Menlo Park 52
San Diego 44
Chicago 43
Kraków 40
Atlanta 37
Phoenix 37
Shanghai 36
Hefei 34
Brooklyn 30
Orem 30
Guangzhou 29
London 29
Nuremberg 27
Toronto 23
University Park 23
Norwalk 21
Brussels 20
Mountain View 20
North Bergen 20
Saint Petersburg 20
Denver 19
Frankfurt am Main 19
Nanjing 19
Redondo Beach 18
Warsaw 18
Montreal 17
Redwood City 16
Stockholm 16
Da Nang 15
Creede 14
Palo Alto 14
San Francisco 14
Seoul 14
Boston 13
Falls Church 13
Haiphong 13
Kunming 13
Naples 13
Rio de Janeiro 13
Boardman 12
Center 12
Jakarta 12
Johannesburg 12
Meru 12
Newark 12
Amsterdam 11
Belo Horizonte 11
Brno 11
Columbus 11
Engelhard 11
Nürnberg 11
Bologna 10
Curitiba 10
Springfield 10
Verona 10
Brasília 9
Detroit 9
Dhaka 9
Florence 9
Quito 9
Vienna 9
Totale 36.332
Salva come PNG Salva come JPEG
Nome #
Awake thoracoscopic biopsy of anterior mediastinal masses 888
Psoriasiform sarcoidosis: an unusual variety 719
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 593
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy 527
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas 527
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 505
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 498
Treatment of multiple myeloma: A randomized study of three different regimens 490
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial 488
Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocol 484
Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas 481
Il trattamento chirurgico delle rinosinusiti nei pazienti oncoematologici: confronto tra procedure 480
Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients 478
Non-Hodgkin lymphomas of the central nervous system 477
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma 475
Comprehensive analysis of PTEN status in Sezary syndrome 474
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 467
Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma 464
Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study 464
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients 461
WILL MOLECULAR-BIOLOGY CONTRIBUTE TO REFINE PROGNOSIS AND TO SELECT TREATMENT 460
SEQUENTIAL THERAPY WITH VAPLD AND BORTEZOMIB AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSION BEFORE STEM CELL MOBILIZATION 459
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 457
FISH analysis for CML monitoring? 454
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 451
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 451
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 450
Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion 450
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses 449
Biological and clinical advances in multiple myeloma: A review 446
Mitoxantrone in combination with etoposide and cytarabine for treatment of poor prognosis acute non lymphoid leukemia patients 446
Clinical implication of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non Hodgkin Lymphomas 445
Short term treatment with Escheria coli recombinant human granulocyte- macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease 441
Peripheral polyneuropathy during treatment with alpha-2 interferon 441
Allogeneic stem cell transplantation for patients with advanced primary cutaneous T-cell lymphoma 440
Menstrual function in patients undergoing chemotherapy for Hodgkin's disease 439
Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma? 438
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody 436
Reduced intensity allogeneic transplantation in primary cutaneous t-cell lymphomas. 431
Long term follow up of the italian trial of Interferon-A versus conventional chemotherapy in Chronic Myeloid Leukemia 430
Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy 430
Multiple skin tumors in long-term treatment with hydroxyurea 429
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 428
EVALUATING SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR CHRONIC MYELOID-LEUKEMIA IN CHRONIC PHASE - A COMPARISON OF TRANSPLANT VERSUS NO-TRANSPLANT IN A COHORT OF 258 PATIENTS 1ST SEEN IN ITALY BETWEEN 1984 AND 1986 428
TREATMENT OF PH-POSITIVE CHRONIC MYELOID-LEUKEMIA WITH ALPHA-INTERFERON (ROFERON-A) - THE ITALIAN COOPERATIVE STUDY-GROUP EXPERIENCE 428
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group 427
Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia 426
PROGNOSTIC VALUE OF CEREBROSPINAL FLUID FLOW CYTOMETRY ANALYSIS IN AGGRESSIVE NHL PATIENTS AT HIGH RISK FOR LEPTOMENINGEAL DISEASE: FCM plus MAY PREDICT AN HIGH RISK OF CNS RELAPSE 424
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions. 424
A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias 420
Percutaneous kyphoplasty: indications and technique in the treatment of vertebral fractures from myeloma 419
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 419
EARLY CHEMOTHERAPY INTENSIFICATION WITH BEACOPP IN HIGH-RISK, INTERIM-PET POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA, IMPROVES THE OVERALL TREATMENT OUTCOME OF ABVD: A GITIL MULTICENTER CLINICAL STUDY 417
Bone marrow processing with a gravity sedimentation technique: experience of 13 cases 415
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial 413
INTERFERON ALFA-2A AS COMPARED WITH CONVENTIONAL CHEMOTHERAPY FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA 412
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients 411
Pegylated, liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma: An update 410
Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis 409
Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment 407
CONFIRMATION AND IMPROVEMENT OF SOKAL PROGNOSTIC CLASSIFICATION OF PH+ CHRONIC MYELOID-LEUKEMIA - THE VALUE OF EARLY EVALUATION OF THE COURSE OF THE DISEASE 406
CLIPI: A new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 405
Percutaneus osteoplasty in the treatment of extraspinal painful multiple myeloma lesions 404
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 404
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 399
Chemotherapy in cutaneous T-cell lymphoma 399
Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients 398
Brain metabolic changes in hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study 398
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients 397
KARYOTYPIC CONVERSION BY INTERFERON AS PREPARATIVE TREATMENT FOR AUTOLOGOUS BMT IN PH POSITIVE CML 396
Disseminated pagetoid reticulosis presenting as cytotoxic CD4/CD8 double negative cutaneous T-cell lymphoma 393
Intermediate stage Hodgkin's disease: Preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy 392
Surgical management of rhinosinusitis in onco-hematological patients 388
Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. 388
Monitoring treatment and survbival in Cronic Myeloid Leukemia 385
Reduced-intensity conditioning combined with standard GvHD prophylaxis is tolerable and highly effective for patients with primary cutaneous T-cell lymphomas undergoing allogeneic transplantation in advanced disease stage. 383
Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma 383
Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease 382
Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymph 378
PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION 373
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 372
[Current aspects of treatment of multiple myeloma] 363
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 359
Initial staging of hodgkin's disease: Role of contrast-enhanced 18F FDG PET/CT 358
Early detection of IgH monoclonal rearrangenent in follicular spicules of the nose preceding multiple myeloma diagnosis. Case report and review of the literature 354
Physician-Patient Relationship: Intervention Opportunities for Multiple Myeloma patients' Needs 346
Granulomatous mycosis fungoides responsive to gemcitabine 345
Molecular expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinases in plasmacellular disorders: A molecular panel to nvestigate disease progression 287
Recurrent Sweet's syndrome in a patient with multiple myeloma 260
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir 251
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) 214
Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations 211
The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma 207
Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients 207
Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance 203
Hepatic follicular lymphoma in an old patient with Crohn’s disease: a rare case and review of the literature 203
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 201
Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin 200
Preliminary results of a counselling programme for fertility preservation in female cancer patients: the experience of the GEMME DORMIENTI network 196
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant 194
Totale 40.932
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.407
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.407
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022884 0 0 0 76 30 99 44 42 76 87 55 375
2022/20231.581 167 150 77 160 131 349 180 79 137 10 112 29
2023/2024737 51 20 61 20 38 298 30 31 18 13 25 132
2024/20252.633 92 559 302 143 43 139 210 135 201 238 295 276
2025/20264.440 313 222 516 346 404 200 502 475 441 418 436 167
2026/20271.726 219 243 841 423 0 0 0 0 0 0 0 0
Totale 43.778